Tarsus Pharmaceuticals, Inc.

NasdaqGS:TARS 株式レポート

時価総額:US$1.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Tarsus Pharmaceuticals マネジメント

マネジメント 基準チェック /44

Tarsus Pharmaceuticals'の CEO はBobby Azamianで、 Nov2016年に任命され、 の在任期間は 7.58年です。 の年間総報酬は$ 3.13Mで、 19.8%給与と80.2%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の2.27%を直接所有しており、その価値は$ 26.54M 。経営陣と取締役会の平均在任期間はそれぞれ3.1年と3.7年です。

主要情報

Bobby Azamian

最高経営責任者

US$3.1m

報酬総額

CEO給与比率19.8%
CEO在任期間7.6yrs
CEOの所有権2.3%
経営陣の平均在職期間3.1yrs
取締役会の平均在任期間3.7yrs

経営陣の近況

Recent updates

Following Up On Tarsus Pharmaceuticals

May 28

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

May 11
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 08

Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Mar 03
Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 01
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

Feb 28
Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nov 12
New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Aug 16
What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Tarsus files for FDA approval of TP-03 to treat mite infestation in eyelids

Sep 07

Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

May 13
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

CEO報酬分析

Tarsus Pharmaceuticals の収益と比較して、Bobby Azamian の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$148m

Dec 31 2023US$3mUS$620k

-US$136m

Sep 30 2023n/an/a

-US$108m

Jun 30 2023n/an/a

-US$91m

Mar 31 2023n/an/a

-US$65m

Dec 31 2022US$4mUS$590k

-US$62m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$7mUS$550k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$3mUS$437k

-US$27m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$416kUS$300k

-US$5m

報酬と市場: Bobbyの 総報酬 ($USD 3.13M ) は、 US市場 ($USD 3.40M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Bobbyの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Bobby Azamian

7.6yrs

在職期間

US$3,130,332

報酬

Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016. He serves as Chief Executive Officer at Tarsus Pha...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Bobak Azamian
Co-Founder7.6yrsUS$3.13m2.27%
$ 23.4m
Jeffrey S. Farrow
CFO & Chief Strategy Officer1.2yrsUS$3.99m0.0019%
$ 19.1k
Seshadri Neervannan
Chief Operating Officer3.9yrsUS$1.74m0.17%
$ 1.8m
Elizabeth Lin
Chief Medical Advisor & Director3.8yrsUS$180.21k0.079%
$ 815.8k
David Nakasone
Head of Investor Relations2.8yrsデータなしデータなし
Bryan Wahl
General Counsel & Corporate Secretary3.4yrsUS$2.53m0.11%
$ 1.1m
Adrienne Kemp
Senior Director of Corporate Communications2.2yrsデータなしデータなし
Matthew Rossen
Vice President of Marketing2.4yrsデータなしデータなし
Scott Youmans
Vice President of Sales2.3yrsデータなしデータなし
Dianne Whitfield
Chief Human Resources Officer3.4yrsUS$3.21m0.090%
$ 932.5k
Aziz Mottiwala
Chief Commercial Officer3.8yrsデータなし0.14%
$ 1.5m
Cara Miller
Senior Vice President of Corporate Affairsless than a yearデータなしデータなし

3.1yrs

平均在職期間

46yo

平均年齢

経験豊富な経営陣: TARSの経営陣は 経験豊富 であると考えられます ( 3.1年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Bobak Azamian
Co-Founder7.5yrsUS$3.13m2.27%
$ 23.4m
Elizabeth Lin
Chief Medical Advisor & Director2.4yrsUS$180.21k0.079%
$ 815.8k
William Link
Independent Director7.4yrsUS$183.33k0.65%
$ 6.7m
Wendy Yarno
Lead Independent Director3.6yrsUS$265.83k0.019%
$ 191.0k
Bhaskar Chaudhuri
Independent Director4.5yrsUS$178.58k0.0053%
$ 54.5k
Scott William Morrison
Independent Director1.7yrsUS$186.46k0.0035%
$ 36.4k
Rosemary Crane
Independent Director2.8yrsUS$183.71k0.0053%
$ 54.5k
Andrew Goldberg
Independent Director3.8yrsUS$171.71k0.0079%
$ 81.8k

3.7yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: TARSの 取締役会経験豊富 であると考えられます ( 3.7年の平均在任期間)。